Hemispherx BioPharma, Inc (HEB) Short Interest Down 7.8% in March
Hemispherx BioPharma, Inc (NYSEAMERICAN:HEB) was the recipient of a large decrease in short interest during the month of March. As of March 15th, there was short interest totalling 696,371 shares, a decrease of 7.8% from the February 28th total of 755,672 shares. Based on an average daily trading volume, of 869,147 shares, the short-interest ratio is presently 0.8 days. Currently, 1.5% of the shares of the stock are short sold.
Shares of NYSEAMERICAN:HEB opened at $0.16 on Wednesday. Hemispherx BioPharma has a one year low of $0.15 and a one year high of $0.50.
COPYRIGHT VIOLATION NOTICE: This piece was originally published by Watch List News and is the property of of Watch List News. If you are reading this piece on another publication, it was copied illegally and republished in violation of U.S. & international copyright & trademark laws. The correct version of this piece can be viewed at https://www.watchlistnews.com/hemispherx-biopharma-inc-heb-short-interest-down-7-8-in-march/2920048.html.
Hemispherx Biopharma, Inc, a specialty pharmaceutical company, engages in the clinical development of drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders in the United States. The company's products include Alferon N Injection, an injectable formulation of natural alpha interferon to treat a category of genital warts, a sexually transmitted disease; and Ampligen for the treatment of chronic fatigue syndrome (CFS).
Featured Article: How is an ETF different from a mutual fund?
Receive News & Ratings for Hemispherx BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemispherx BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.